| Index | — | P/E | — | EPS (ttm) | — | Insider Own | 3.64% | Shs Outstand | 33.29M | Perf Week | -10.50% |
| Market Cap | 331.91M | Forward P/E | — | EPS next Y | -2.20 | Insider Trans | 21.05% | Shs Float | 2.06M | Perf Month | 3.96% |
| Enterprise Value | 162.91M | PEG | — | EPS next Q | -0.46 | Short Float | 41.28% | Perf Quarter | -18.61% | ||
| Income | -46.00M | P/S | 10.37 | EPS this Y | — | Short Ratio | 4.75 | Perf Half Y | — | ||
| Sales | 32.00M | P/B | 1.92 | EPS next Y | — | ROA | -19.86% | Short Interest | 850.18K | Perf YTD | -28.79% |
| Book/sh | 5.20 | P/C | 1.88 | EPS next 5Y | — | ROE | 79.74% | 52W High | 15.29 -34.79% | Perf Year | — |
| Cash/sh | 5.32 | P/FCF | — | EPS past 3/5Y | — | ROIC | -19.24% | 52W Low | 8.03 24.16% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 82.80% | Volatility | 8.31% 6.78% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | 5.09 | EPS Y/Y TTM | — | Oper. Margin | -136.30% | ATR (14) | 0.75 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 12.80 | Sales Y/Y TTM | — | Profit Margin | -151.62% | RSI (14) | 50.19 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 13.28 | EPS Q/Q | -107.55% | SMA20 | 4.08% | Beta | -0.08 | Target Price | 25.00 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | 16.67% | SMA50 | -0.11% | Rel Volume | 1.38 | Prev Close | 10.07 |
| Employees | 167 | LT Debt/Eq | 0.05 | Earnings | Nov 05 | SMA200 | -12.63% | Avg Volume | 201.40K | Price | 9.97 |
| IPO Date | May 08, 2026 | Option/Short | No / Yes | EPS/Sales Surpr. | -57.75% 10.95% | Net Debt/EBITDA | — | Volume | 277,262 | Change | -0.99% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-02-26 | Initiated | BTIG | Buy | $19 |
| Jun-02-26 | Reiterated | Goldman Sachs | $31 |
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | |
|---|---|---|
| Total Revenue | 32 | |
| Cost of Goods Sold Incl. D&A | 6 | |
| Gross Profit | 26 | |
| Selling, General and Administrative Excl. Other | 66 | |
| Research and Development | 7 | |
| Other Operating Expense | -1 | |
| Operating Income | -46 | |
| Interest Expense | 1 | |
| Unusual Expense | — | |
| Non-Operating Income (Expense) | 1 | |
| Net Income Before Taxes | -46 | |
| Income Taxes | 0 | |
| Consolidated Net Income | -46 | |
| Net Income From Continuing Operations | -46 | |
| Net Income | -46 | |
| EPS (Recurring) | -0.02 | |
| EPS (Basic, Before Extraordinaries) | -0.02 | |
| EPS (Diluted) | -0.02 | |
| EBITDA | -45 | |
| Other After Tax Adjustments | — | |
| Stock Option Compensation Expense | — | |
| Price To Earnings Ratio | — | |
| Price To Sales Ratio | — | |
| Gross Margin | 81.25 | |
| Operating Margin | -143.75 | |
| Net Margin | -143.75 | |
| Shares Outstanding | 23 | |
| Market Capitalization | — | |
| Operating Lease Expense | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Leavitt Chase C. | Officer | Sep 11 '26 | Buy | 10.30 | 2,000 | 20,600 | 5,000 | Sep 15 |
| Rawat Prashant B. | Chief Operating Officer | Sep 02 '26 | Option Exercise | 3.38 | 15,000 | 50,700 | 30,000 | Sep 04 |
| Tansey Casey M | Director | Aug 18 '26 | Buy | 12.07 | 16,441 | 198,523 | 318,332 | Aug 20 |
| Tansey Casey M | Director | Aug 17 '26 | Buy | 11.85 | 17,166 | 203,433 | 301,891 | Aug 17 |
| Tansey Casey M | Director | Aug 14 '26 | Buy | 11.66 | 15,821 | 184,403 | 284,725 | Aug 17 |
| Tansey Casey M | Director | Aug 13 '26 | Buy | 11.51 | 35,572 | 409,338 | 268,904 | Aug 17 |
| Green Park & Golf Ventures - Houston, LLC | 10% Owner | May 11 '26 | Buy | 15.00 | 60,537 | 908,055 | 60,537 | Jun 29 |
| Green Park & Golf Ventures II, LLC | 10% Owner | May 11 '26 | Buy | 15.00 | 114,333 | 1,714,995 | 81,000 | Jun 29 |
| Green Park & Golf Ventures II, LLC | 10% Owner | May 11 '26 | Option Exercise | 0.88 | 177,619 | 155,757 | 70,053 | Jun 29 |
| Green Park & Golf Ventures II, LLC | 10% Owner | May 11 '26 | Sale | 4.21 | 6,731 | 28,317 | 43,799 | Jun 29 |